Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

计划入组 52 人 · 首次发布于 2014 年 4 月 1 日

Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients

计划入组 9 人 · 首次发布于 2024 年 3 月 5 日

Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada

计划入组 6,000 人 · 首次发布于 2013 年 12 月 12 日

bempedoic acid(Nexletol, Nexlizet, Nilemdo, Nustendi)

C₁₉H₃₆O₅ · Rx

familial hypercholesterolemia program

Hypercholesterolemia (CAMP4 Therapeutics)

The Familial Hypercholesterolemia Foundation

United States

Madrigal Pharmaceuticals

United States

Actinium

United States

ANGPTL3 Inhibitors Market Poised to Reach $3.48 Billion by 2035 as Pipeline Diversifies Beyond Monoclonal Antibodies

Editas Medicine Achieves 90% LDL Cholesterol Reduction with EDIT-401 Gene Therapy in Preclinical Studies

Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance One-Time Gene Editing Treatments for Cardiovascular Disease